QUOTE AND NEWS
Forbes  Dec 2  Comment 
Anyone older than 10 can build their own robot using this kit: a collection of LEGO Technic pieces and a robot brain you can easily program.
TechCrunch  Sep 19  Comment 
LEGO Mindstorms EV3. Even the name is formidable, but just wait until you connect the dots and fire these dragon-esque robots up. The EV3 set of robotic, programmable LEGOs is the very best version of this 14-year-old product line we've ever...
Cloud Computing  Feb 14  Comment 
LEGO World — Autodesk, Inc. (NASDAQ: ADSK), a leader in 3D design, engineering and entertainment software, has partnered with The LEGO Group to provide 3D interactive building instructions for LEGO MINDSTORMS EV3, a new ...
Forbes  Jan 13  Comment 
LEGO announced this week that it will be offering its third generation of its Mindstorms line. The new system, the EV3, features a lot of improved features in both its hardware and software, with an eye towards improving its use in the classroom...
TechCrunch  Jan 10  Comment 
LEGO just introduced the third generation LEGO Mindstorm sets. Like previous versions, a central computer controls motors and servos, essentially bringing the LEGO kit to life. This new version is heavily upgraded. And as a father, I must attest,...
New York Times  Jan 9  Comment 
Lego Mindstorms EV3 is a long-awaited update to the Lego robotics kits used by many schools. The idea, Lego says, is to bring snap-together robots into every home.
TechCrunch  Jan 7  Comment 
Lego is back with another generation of MindStorms, the company's consumer robotics line aimed at introducing application programming to a younger generation. Kids these days grow up with so much focus on the virtual self, but MindStorms works as...
Forbes  Mar 16  Comment 
Jefferies today increased the price target of Covidien as an FDA panel is likely to support the new stroke device produced by eV3, which it acquired. Jefferies set a price target of $59 with a buy rating.
StreetInsider.com  Jul 12  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Covidien+%28COV%29+Completes+ev3+Acquisition/5798629.html for the full story.
Wall Street Journal  Jul 11  Comment 
Stocks have tumbled since late April, creating some potential to buy on the cheap. But merger arbitragers, who trade the stocks of acquisition targets, have found things getting ever more expensive.




RELATED WIKI ARTICLES

Related Articles

 
TOP CONTRIBUTORS

ev3 Inc. (NASDAQ: EVVV) manufactures and markets medical devices for treating peripheral vascular and neurovascular diseases. Vascular disease refers to diseases pertaining to blood vessels outside of the heart and the brain.[1] In 2009, ev3's net sales were $422.5 million.

ev3 has become the the second largest producer of neurovascular products in terms of total revenue.[2] The company develops and manufactures the broadest product portfolio with over 100 [3] products. ev3 markets its products worldwide, with a majority of its customer base coming from the healthcare space.[4]

Company Overview

ev3's customers include a broad cross-section of physicians, including interventional radiologists, neuroradiologists, vascular surgeons, neuro surgeons, other endovascular specialists and interventional cardiologists. The company sells its products in more than 65 countries through a direct sales force in the United States, Canada, Europe, Australia and other countries and distributors in selected other international markets.[5]

As of December 31, 2009, ev3 had 114 direct sales representatives selling its peripheral vascular products and 25 direct sales representatives selling its neurovascular products in the United States.[5] ev3 has a manufacturing facility located in Plymouth, Minnesota, at which it manufactures most of its peripheral vascular products, and a manufacturing facility located in Irvine, California, at which it manufactures most of its neurovascular products and a few of its peripheral vascular products. [5]

Business and Financial Metrics

First Quarter 2010 Results[6]

ev3 reported first quarter net sales of $123.9 Million, an increase of 23% from the prior-year period. Excluding $2.9 million of positive impact due to foreign currency exchange rates, net sales increased 21% versus the prior year quarter. First quarter GAAP EPS increased to $0.09, and cash and cash equivalents increased to $116.8 Million.

ev3's GAAP net income for the first quarter of 2010 was $9.9 million, or $0.09 per diluted share, compared to a net loss of $(1.8) million, or $(0.02) per diluted share, in the first quarter of 2009. Non-GAAP adjusted net income in the first quarter of 2010 was $22.3 million, or $0.20 per diluted share, compared to adjusted net income of $7.1 million, or $0.07 per diluted share, in the first quarter of 2009.

The company achieved another quarter of significant sales growth in both the neurovascular and peripheral vascular segments that outpaced market growth rates in U.S. and international markets. ev3's neurovascular segment, which grew 44% in the first quarter compared to the prior year quarter, reflects the broad penetration the company is making across its entire product line and the positive response to the international launch of its Pipeline Embolization Device and Solitaire FR Revascularization Device for ischemic stroke.

Image:Ev3data.jpg

Business Segments

ev3 is has two business segments: peripheral vascular and neurovascular.

Peripheral vascular segment

This segment includes products that are used primarily in peripheral vascular procedures by interventional radiologists, vascular surgeons and interventional cardiologists and in targeted cardiovascular procedures. [5]

Neurovascular segment

This segment includes products that are used primarily by neuroradiologists, interventional neurologists and neurosurgeons.[5]

Acquisitions

In June of 2009, ev3 acquired Chestnut Medical Technologies, Inc., a privately-held California-based company focused on developing minimally invasive therapies for interventional neuroradiology.[5] ev3 acquired 100 percent of the equity interests of Chestnut for total consideration valued at $116.7 million, consisting of upfront consideration of common stock and cash valued at $79.4 million, as well as an additional milestone-based contingent payment of up to $75.0 million, payable in a combination of common stock and equity, upon FDA pre-market approval of the Pipeline Embolization Device. [5] The transaction broadens ev3's neurovascular product portfolio by adding the Pipeline Embolization Device for the treatment of cerebral aneurysms and the Alligator Retrieval Device for foreign body retrieval to its existing neurovascular embolic products and neuro access technologies.[5]

Trends and Forces

Regulatory Hurdles

The Food and Drug Administration (FDA) serves as an entity that establishes or modifies foods, drugs, biologics, cosmetics, radiation-emitting electronic products, and medical devices for approval for use by the general public. ev3's products may or may not be approved by the FDA ,and this will have a considerable impact on net income and revenues in the future. ev3's products consist of Class I-III devices which all have different regulations.

ev3 is currently conducting a clinical trial called the DEFINITIVE trial, a post-market study evaluating the benefits of their Silverhawk product. ev3 has also enrolled its first patients in the DEFINITIVE Ca++ US IDE study which evaluates the Rockhawk device and the SpiderFX Embolic Protection Device for the treatment of calcified peripheral artery lesions. The main reason for these trials is to encourage physician use of atherectomy as a front line treatment for patients with these diseases. [7]

Recall on FDA approved device

On December 1st 2009, ev3's Protege Everflex Self-Expanding Biliary Stent System was recalled by the FDA because of ev3 determined that a lot of 150mm Protege EverFlex Biliary Stent System contains a 100mm length Self-Expanding stent. All of the Class II stents need to be recalled because the implantation of a stent 50mm shorter than expected may not cover the full length of the target lesion and may require subsequent intervention [8]

Leadership in the Endovascular Market

There are an estimated 35,000 thoracic aortic surgical and endovascular interventions performed every year in the developed world. The market in which ev3 operates is said to reach $250 Million Globally by 2012 based on these progressive numbers.[9] Based on technological advances in therapies around the world, ev3 is positioned to address the increasing demand for therapy through their innovative product given FDA approval of novel technologies.

Diverse Portfolio

ev3 has one of the most complete portfolios in the peripheral vascular business. Although the FoxHollow acquisition has been disappointing, the other segments within the peripheral segment have grown above the market rate in the past 3 quarters. ev3 is also moving toward profitability on a GAAP basis and this will be attractive to driving more solid earnings growth. [10]

Competitive Strengths: Vascular Focus and New Management

New Management

ev3 changed its CEO to Bob Palmisano who joined the company in April 2008 from the ophthalmology industry. The CEO has led the company through two mergers, the Summit Autonomous to Alcon Labs in 2000 and Intralase to Advanced Medical Optics in 2007.This experience aids in the transition as the company integrates the Fox Hollow acquisition. ev3 also has a new CFO, Shawn McCormick who joined in January. He worked for Medtronic (one of ev3's competitors) where he headed up the company’s corporate development efforts. Acquiring new management from the competitor leads to new leadership direction and experience from a proven medical company such as Medtronic.

Focus

ev3 is one of the only medical device companies in the United States focused on the endovascular device market with a global presence in the peripheral vascular and neurovascular sub-markets.[11] Some of the noted competitive strengths come from targeting under-innovated and emerging markets, leveraging products across major endovascular sub-markets, investing in clinical research, expanding business through product innovation and strategic acquisitions and a seasoned management team. If ev3 is able to harness these strengths and move into different markets as the global need for endovascular products gains traction, they will be able to tap the market's full potential and be prepared to market its products.

Competition

ev3's competitors include companies such as Boston Scientific Corporation (NYSE: BSX), Medtronic Inc. (NYSE: MDT - News), C.R. Bard (NYSE: BCR), Cordis, and others in the endovascular market. [12]

ev3's peripheral vascular devices are mostly catheter-based. These are deployed to treat diseased vessels outside of the heart that have been become blocked or calcified. [13]

The company has the number 2 position in the neurovascular market and roughly 20% share of the $670 million globally. [14]

Medtronic is a competitor in the vascular market with 10% market share. Cordis (Part of the Johnson & Johnson family of companies) had total sales of $3.1 billion in 2008, but most of this revenue came from the stent portion of the business. Boston Scientific main products are coronary drug-eluting stents, cardiac rhythm management devices, pacemakers and implantable cardioverter-defibrillators.

ev3 has the least amount of revenue, profit margin, gross profit, and employees among the main competitors.

Competitive Metrics Medtronic Boston Scientific C.R. Bard ev3
Revenues $15.09B 8.11B 2.49B $422 M
Profit Margin15%-29%20%-61%
Gross Profit $11.08B $5.58B $1.50B $279M
Net Income $2.21B $-2.34B $503M $-262M
Employees41,15824,80011,0001,250



References

  1. neurovascular
  2. Annual Report 2008, The World's Broadest Endovascular Product Offerings, Page 01
  3. endovascular Wikipedia: Endovascular surgery
  4. Yahoo Finance ev3 Profile
  5. 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 ev3 Annual Report 2009
  6. ev3 Investor Relations: "ev3 Reports 2010 First Quarter Financial Results" April 29, 2010
  7. Thomas Weisel Partners, ev3, Page 10
  8. ev3 December 01, 2009 Recall
  9. Business Wire: Endovascular Market Forecast to Reach US$250 Million Globally by 2012
  10. [Thomas Weisel Partners, ev3, Page 5]
  11. Corporate Profile ev3
  12. ev3 Beats Zacks Estimate
  13. [Thomas Weisel Partners, ev3, Page 2]
  14. [Thomas Weisel Partners, ev3, Page 3]
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki